The mechanisms of idiopathic pulmonary fibrosis: Can we see the elephant?

Drug Discovery Today: Disease Mechanisms

Volumn 1, Issue 1, 2004, Pages 117-122

  Gibson, Kevin ^a   Kaminski, Naftali ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MATRIX METALLOPROTEINASE; PIRFENIDONE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; NONHUMAN; REVIEW; SIDE EFFECT;

EID: 23744432901     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2004.08.002     Document Type: Review

References (32)

1. Collard, H.R. and King, T.E. Jr. (2003) Demystifying idiopathic interstitial pneumonia. Arch. Intern. Med. 163, 17-29
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165, 277-304
3. Selman, M. et al. (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134, 136-151
4. Selman, M. et al. (2004) Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64, 405-430
5. Piguet, P.F. and Vesin, C. (1994) Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. 7, 515-518
6. Piguet, P.F. et al. (1997) Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int. J. Exp. Pathol. 78, 43-48
7. Piguet, P.F. et al. (1993) Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5, 57-61
8. Flaherty, K.R. et al. (2001) Histopathologic variability in usual and nonspecific interstitial pneumonias. Am. J. Respir. Crit. Care Med. 164, 1722-1727
9. Sime, P.J. et al. (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 100, 768-776
10. Huaux, F et al. (1998) Role of interleukin-10 in the lung response to silica in mice. Am. J. Respir. Cell. Mol. Biol. 18, 51-59
11. Munger, J.S. et al. (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328
12. Zhao, J. et al. (2002) Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L585-L593
13. Helene, M. et al. (1999) T cell independence of bleomycin-induced pulmonary fibrosis. J. Leukoc. Biol. 65, 187-195
14. Hao, H. et al. (2000) Bleomycin-induced pulmonary fibrosis is independent of eosinophils. J. Leukoc. Biol. 68, 515-521
15. Selman, M. et al. (2000) TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L562-L574
16. Zuo, F. et al. (2002) Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.. Proc. Natl. Acad. Sci. USA 99, 6292-6297
17. Betsuyaku, T. et al. (2000) Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157, 525-535
18. Corbel, M. et al. (2001) Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J. Pathol. 193, 538-545
19. Keane, M.P. et al. (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 159, 1437-1443
20. Keane, M.P. et al. (1999) IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163, 5686-5692
21. Brewer, G.J. et al. (2003) Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J. Lab. Clin. Med. 141, 210-216
22. Cosgrove, G.P. et al. (2002) Angiogenesis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 165, A172
23. Ebina, M. et al. (2004) Heterogeneous increase of CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.
24. Kuwano, K. et al. (1999) Expression of B7-1, B7-2, and interleukin-12 in anti-Fas antibody-induced pulmonary fibrosis in mice. Int. Arch. Allergy Immunol. 119, 112-119
25. Kuwano, K. et al. (1999) Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis [see comments]. J. Clin. Invest. 104, 13-19
26. Kuwano, K. et al. (2000) Expression of apoptosis-regulatory genes in epithelial cells in pulmonary fibrosis in mice. J. Pathol. 190, 221-229
27. Uhal, B.D. et al. (1998) Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am. J. Physiol. 275, L1192-L1199
28. Wang, R. et al. (1999) Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. Am. J. Physiol. 277, L1158-L1164
29. Inoshima, I. et al. (2004) Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L727-L733
30. Li, X. et al. (2003) Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am. J. Pathol. 163, 2523-2530
31. Selman, M. and Pardo, A. (2003) The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 29, S93-S87
32. Strieter, R.M. (2003) To clot or not to clot, that is the question in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 167, 1589-1590